SINTX Technologies, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US8293926049
USD
3.84
0.22 (6.08%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About SINTX Technologies, Inc. stock-summary
stock-summary
SINTX Technologies, Inc.
Pharmaceuticals & Biotechnology
SINTX Technologies, Inc., formerly Amedica Corporation, is a commercial biomaterial company. The Company is a vertically integrated silicon nitride orthopedic medical device manufacturer. It is focused on using its silicon nitride ceramic technology platform to develop, manufacture and sell a range of medical devices. It is also engaged in developing wear- and corrosion-resistant implant components for hip and knee arthroplasty. The Company is incorporating its silicon nitride technology into components for use in total hip and knee replacement product candidates. The Company markets and sells its products to surgeons and hospitals in the United States, and certain markets in Europe and South America. The Company produces silicon nitride for use in its commercial products and product candidates in the various forms, such as solid silicon nitride, porous silicon nitride, composite silicon nitride and silicon nitride coating.
Company Coordinates stock-summary
Company Details
1885 West 2100 Street , SALT LAKE CITY UT : 84119
stock-summary
Tel: 1 801 83935161 801 8393534
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 2 Schemes (1.67%)

Foreign Institutions

Held by 4 Foreign Institutions (0.07%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Dr. B. Sonny Bal
Chairman of the Board, President, Chief Executive Officer, Chief Financial Officer
Mr. Mark Froimson
Independent Director
Mr. Eric Stookey
Independent Director
Mr. David Truetzel
Independent Director
Mr. Jeffrey White
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2025)
Net Profit:
-2 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 13 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.96

stock-summary
Return on Equity

-194.88%

stock-summary
Price to Book

3.18